Drug Profile
Revacept - AdvanceCor
Alternative Names: Dimeric glycoprotein VI-Fc; GPVI-Fc; PR-15; RevaceptLatest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator Corimmun
- Developer advanceCor
- Class Antiarrhythmics; Antiplatelets; Antithrombotics; Cardiovascular therapies; Heart failure therapies; Imaging agents; Platelet membrane glycoproteins; Recombinant fusion proteins; Vascular disorder therapies
- Mechanism of Action Platelet membrane glycoprotein VI inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute coronary syndromes; Coronary artery disease; Stroke
- Phase I Peripheral arterial disorders
Most Recent Events
- 04 Apr 2024 Phase-I clinical trials in Peripheral arterial disorders (IV), prior to April 2024 (AdvanceCor pipeline, April 2024)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Acute coronary syndromes(Diagnosis) in Germany (IV, Injection)
- 16 Apr 2021 Revacept is still in phase II trials for Coronary artery disease in Germany (NCT03312855)